Scholarlink

Background <p>Lipid-lowering therapies, particularly statins, have been associated with a reduced risk of cancer. However, the potential additional protective effects of ezetimibe remain unclear in real-world settings. This study investigated whether statin/ezetimibe combination therapy provided further cancer risk reduction beyond statin monotherapy.</p> Methods <p>A nationwide retrospective cohort study was conducted using the Korean National Health Insurance Service database. Patients with dyslipidemia (total cholesterol ≥ 240&#xa0;mg/dL) diagnosed between 2004 and 2009 were included and categorized into statin users, statin/ezetimibe users, and nonusers. Cancer incidence over 5- and 10-year follow-up periods was assessed using Cox proportional hazards models adjusted for demographic, clinical, and lifestyle factors. Inverse probability of treatment weighting (IPTW) was applied to account for potential confounders, and sensitivity analyses were performed to assess the stability of the findings.</p> Results <p>Among 68,353 patients, 9,267 were statin users, 383 were statin/ezetimibe users, and 58,703 were nonusers. Statin users exhibited a reduced cancer risk at 5&#xa0;years (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI] 0.80–0.89) and 10&#xa0;years (aHR, 0.91; 95% CI 0.87–0.94). Statin/ezetimibe users demonstrated a greater reduction in cancer risk (5&#xa0;years: aHR, 0.30; 95% CI 0.28–0.32; 10&#xa0;years: aHR, 0.70; 95% CI 0.67–0.73). Trend analysis confirmed an incremental trend in cancer risk reduction with increasing lipid-lowering therapy intensity (<i>P</i> for trend &lt; 0.001).</p> Conclusion <p>This real-world study suggests that ezetimibe, when combined with statins, is associated with additional cancer risk reduction beyond statin monotherapy, as observed across both overall and direct comparative analyses. Further research is warranted to confirm the independent effects of ezetimibe and its potential role in cancer prevention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world evidence on the additional cancer risk reduction of ezetimibe: a 10-year nationwide retrospective cohort study emulating a target trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Yohwan Lim,
  • Eunji Kim,
  • Eunjung Hwang,
  • Koanhoi Kim,
  • Yonghae Son,
  • Sang Yeoup Lee,
  • Young Hye Cho,
  • Eun-Ju Park,
  • Youngin Lee,
  • Sae Rom Lee,
  • Jung-In Choi,
  • Han-Sol Jeong,
  • Su-Jung Park,
  • Soo Min Son,
  • Ryuk Jun Kwon

摘要

Background

Lipid-lowering therapies, particularly statins, have been associated with a reduced risk of cancer. However, the potential additional protective effects of ezetimibe remain unclear in real-world settings. This study investigated whether statin/ezetimibe combination therapy provided further cancer risk reduction beyond statin monotherapy.

Methods

A nationwide retrospective cohort study was conducted using the Korean National Health Insurance Service database. Patients with dyslipidemia (total cholesterol ≥ 240 mg/dL) diagnosed between 2004 and 2009 were included and categorized into statin users, statin/ezetimibe users, and nonusers. Cancer incidence over 5- and 10-year follow-up periods was assessed using Cox proportional hazards models adjusted for demographic, clinical, and lifestyle factors. Inverse probability of treatment weighting (IPTW) was applied to account for potential confounders, and sensitivity analyses were performed to assess the stability of the findings.

Results

Among 68,353 patients, 9,267 were statin users, 383 were statin/ezetimibe users, and 58,703 were nonusers. Statin users exhibited a reduced cancer risk at 5 years (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI] 0.80–0.89) and 10 years (aHR, 0.91; 95% CI 0.87–0.94). Statin/ezetimibe users demonstrated a greater reduction in cancer risk (5 years: aHR, 0.30; 95% CI 0.28–0.32; 10 years: aHR, 0.70; 95% CI 0.67–0.73). Trend analysis confirmed an incremental trend in cancer risk reduction with increasing lipid-lowering therapy intensity (P for trend < 0.001).

Conclusion

This real-world study suggests that ezetimibe, when combined with statins, is associated with additional cancer risk reduction beyond statin monotherapy, as observed across both overall and direct comparative analyses. Further research is warranted to confirm the independent effects of ezetimibe and its potential role in cancer prevention.